Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-κB: Implications for angioprevention and antiangiogenic therapy

Oncogene

Volumn 24, Issue 7, 2005, Pages 1188-1202

  Singh, Rana P ^a   Dhanalakshmi, Sivanandhan ^a   Agarwal, Chapla ^a,b   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Akt; Apoptosis; Cell cycle arrest; Endothelial cells; NF B; Silibinin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOCHROME C; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIGEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BAX; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN P53; SILIBININ; SURVIVIN; WORTMANNIN;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOSIS INHIBITION; PLEIOTROPY; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; APOPTOSIS; BIOLOGICAL ASSAY; CELL CYCLE; CELL MOVEMENT; CELLS, CULTURED; COLLAGEN; DOWN-REGULATION; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; HUMANS; LAMININ; MEMBRANE POTENTIALS; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIA; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SILYMARIN;

EID: 14644410403     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1208276     Document Type: Article

References (67)

1. Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA and Agarwal R. (2003). Oncogene, 22, 8271-8282.
2. Ali IU, Senger DR and Smith LEH. (2001). Urology, 57, 143-147.
3. Altieri DC. (2003). Nat. Rev. Cancer, 3, 46-54.
4. Baeuerle PA. (1998). Curr. Biol., 8, R19-R22.
5. Baeuerle PA and Baltimore D. (1996). Cell, 87, 10-13.
6. Baldwin AS. (1996). Annu. Rev. Immunol., 14, 649-681.
7. Boehm T, Folkman J, Browder T and O'Really MS. (1997). Nature, 390, 404-407.
8. Brakenhielm E, Cao R and Cao Y. (2001). FASEB J., 15, 1798-1800.
9. Brawer MK. (1996). Cancer, 78, 345-349.
10. Brekken RA, Li C and Kumar S. (2002). Int. J. Cancer, 100, 123-130.
11. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence Jr JC and Abraham RT. (1996). EMBO J., 15, 5256-5267.
12. Carmeliet P. (2002). Nat. Med., 6, 389-395.
13. Carmeliet P and Jain RK. (2000). Nat. Med., 407, 249-257.
14. Chen JH, Hsiao G, Lee AR, Wu CC and Yen MH. (2004). Biochem. Pharmacol., 67, 1337-1345.
15. Cory S, Huang DC and Adams JM. (2003). Oncogene, 22, 8590-8607.
16. Cossarizza A, Baccarani-Contri M, Kalishnikova G and Franceschi C. (1993). Biochem. Biophys. Res. Commun., 30, 40-45.
17. Dhanalakshmi S, Singh RP, Agarwal C and Agarwal R. (2002). Oncogene, 21, 1759-1767.
18. Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wahala K, Montesano R and Schweigerer L. (1997). Cancer Res., 57, 2916-2921.
19. Gimbrone Jr MA, Leapman S, Cotran R and Folkman J. (1972). J. Exp. Med., 136, 261-276.
20. Gingis-Velitski S, Zester A, Flugelman MY, Vlodavsky I and Ilan N. (2004). J. Biol. Chem., 279, 23536-23541.
21. Grana X and Reddy P. (1995). Oncogene, 11, 211-219.
22. Green GR and Reed JC. (1998). Science, 281, 1309-1312.
23. Gross A, McDonnell JM and Korsmeyer SJ. (1999). Genes Dev., 13, 1899-1911.
24. Gu Q, Wang D, Wang X, Peng R, Liu J, Jiang T, Wang J, Wang S and Deng H. (2004). Radiat. Res., 161, 692-702.
25. Gustin JA, Ozes ON, Akca H, Pincheira R, Mayo LD, Li Q, Guzman JR, Korgaonkar CK and Donner DB. (2004). J. Biol. Chem., 279, 1615-1620.
26. Hoffmann A, Levchenko A, Scott ML and Baltimore D. (2002). Science, 298, 1241-1245.
27. Hofseth LJ, Hussain SP and Harris CC. (2004). Trends Pharmacol. Sci., 25, 177-181.
28. Jiang C, Agarwal R and Lu J. (2000a). Biochem. Biophys. Res. Commun., 276, 371-378.
29. Jiang C, Ganther H and Lu J. (2000b). Mol. Carcinog., 29, 236-250.
30. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ and Tarnawski AS. (1999). Nat. Med., 5, 1418-1423.
31. Kaufmann S, Desnoyers S, Ottaviano Y, Davidson N and Poirier G. (1993). Cancer Res., 53, 3976-3985.
32. Kerbel RS. (2000). Carcinogenesis, 21, 505-515.
33. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N. (1993). Nature, 362, 841-844.
34. Kitaura J, Asai K, Maeda-Yamamoto M, Kawakami Y, Kikkawa U and Kawakami T. (2000). J. Exp. Med., 192, 729-740.
35. Levkau B, Scatena M, Giachelli CM, Ross R and Raines EW. (1999). Nat. Cell Biol., 1, 227-233.
36. Li A, Dubey S, Varney ML, Dave BJ and Singh RK. (2003). J. Immunol., 170, 3369-3376.
37. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmed M, Alnemri ES and Wang X. (1997). Cell, 91, 479-489.
38. Li Y and Sarkar FH. (2002). Clin. Cancer Res., 8, 2369-2377.
39. Madge LA and Peber JS. (2000). J. Biol. Chem., 275, 15458-15465.
40. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin Jr AS and Mayo MW. (2000). Mol. Cell. Biol., 20, 1626-1638.
41. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA and Giachelli CM. (2000). J. Biol. Chem., 275, 20959-20962.
42. Marchetti P, Castedo M, Susin SA, Zamzami N, Hirsch T, Macho A, Haeffner A, Hirsch F, Geuskens M and Kroemer G. (1996). J. Exp. Med., 184, 1155-1160.
43. Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y and Jones DR. (2003). J. Biol. Chem., 278, 18980-18989.
44. O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, Nath AK, Pober JS and Altieri DC. (2000). Am. J. Pathol., 156, 393-398.
45. Okada H and Mak TW. (2004). Nat. Rev. Cancer, 4, 592-603.
46. Ozes OM, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB. (1999). Nature, 401, 82-85.
47. Paggi MG, Baldi A, Bonetto F and Giordano A. (1996). J. Cell. Biochem., 62, 418-430.
48. Qi JH, Mastumoto T, Huang K, Olausson K, Christofferson R and Claesson-Welsh L. (1999). Angiogenesis, 3, 371-380.
49. Rak J, Yu JL, Klement G and Kerbel RS. (2000). J. Invest. Dermatol. Symp. Proc., 5, 24-33.
50. Ruoslahti E. (2002). Nat. Rev., 2, 83-90.
51. Saelens X, Festjens N, Walle LV, van Gurp M, van Loo G and Vandenabeele P. (2004). Oncogene, 23, 2861-2874.
52. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK and Oh BH. (2001). Biochemistry, 40, 1117-1123.
53. Singh RP and Agarwal R. (2003). Curr. Cancer Drug Targets, 3, 205-217.
54. Singh RP and Agarwal R. (2004). Curr. Cancer Drug Targets, 4, 1-13.
55. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C and Agarwal R. (2002). Cancer Res., 62, 3063-3069.
56. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C and Agarwal R. (2003). Cancer Epidemiol. Biomarkers Prev., 12, 933-939.
57. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M and Jeggo PA. (2004). Cancer Res., 64, 2390-2396.
58. Tosetti F, Ferrari N, Deflora S and Albini A. (2002). FASEB J., 16, 2-14.
59. Toyoshima H and Hunter T. (1994). Cell, 78, 67-74.
60. Tran J, Master Z, Yu JL, Rak J, Dumont DJ and Kerbel RS. (2002). Proc. Natl. Acad. Sci. USA, 99, 4349-4354.
61. van Moorselaar RJ and Voest EE. (2002). Mol. Cell Endocrinol., 197, 239-250.
62. Waddick KG and Uckun FM. (1999). Biochem. Pharmacol., 57, 9-17.
63. Wellington K and Jarwis B. (2001). BioDrugs, 15, 465-489.
64. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D. (1993). Nature, 366, 701-704.
65. Yamamoto Y and Gaynor RB. (2001). J. Clin. Invest., 107, 135-142.
66. Yoo HG, Jung SN, Hwang YS, Park JS, Kim MH, Jeong M, Ahn SJ, Ahn BW, Shin BA, Park RK and Jung YD. (2004). Int. J. Mol. Med., 13, 81-86.
67. Zandi E and Karin M. (1999). Mol. Cell. Biol., 19, 4547-4551.